Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab

by Pelaia C, Vatrella A, Busceti MT, Gallelli L, Terracciano R, Savino R, Pelaia G
Published 2017-10-01

Pharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPD

by Pelaia G, Vatrella A, Busceti MT, Gallelli L, Calabrese C, Terracciano R, Lombardo N, Maselli R
Published 2015-10-01

Short-Term Evaluation of Dupilumab Effects in Patients with Severe Asthma and Nasal Polyposis

by Pelaia C, Lombardo N, Busceti MT, Piazzetta G, Crimi C, Calabrese C, Vatrella A, Pelaia G
Published 2021-09-01

Update on optimal use of omalizumab in management of asthma

by Pelaia G, Gallelli L, Renda T, Romeo P, Busceti MT, Grembiale RD, Maselli R, Marsico SA, Vatrella A
Published 2011-06-01

Role of biologics in severe eosinophilic asthma – focus on reslizumab

by Pelaia G, Vatrella A, Busceti MT, Gallelli L, Preianò M, Lombardo N, Terracciano R, Maselli R
Published 2016-07-01